Verastem AI Stock Analysis
Verastem (0LOV) AI Stock Analysis
Verastem
(LSE:0LOV)
No summary available
Verastem (0LOV) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $1.15B
- Dividend Yield
- ―
- Average Volume (3M)
- 10.56K
- Price to Earnings (P/E)
- -4.9
- Beta (1Y)
- 1.11
- Revenue Growth
- 649.65%
- EPS Growth
- 54.01%
- Country
- UK
- Employees
- 102
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Verastem Business Overview & Revenue Model
Company Description
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by...
Verastem Earnings Call Summary
The call was strongly positive overall. Management reported 114% year-over-year product revenue growth, increasing refill momentum, a strengthened balance sheet with funding into the first half of 2028, encouraging VS-7375 efficacy across pancreatic, colorectal and lung cancers, favorable safety data, and multiple advancing Phase II and Phase III programs. The main negatives were moderated new patient starts, anticipated competitive pressure in pancreatic cancer, a larger adjusted net loss, and remaining clinical, regulatory and site-enrollment execution requirements.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Verastem expects SG&A expenses will remain consistent on a quarterly basis in the fourth quarter of 2026, with current cash, October follow-on offering proceeds and expected AVMAPKI FAKZYNJA CO-PACK revenues funding operations into the first half of 2028, including completing VS-7375 Phase II studies and starting 3 pivotal Phase III studies; pancreatic and colorectal Phase II enrollment is expected to complete around the end of the year and lung enrollment in the first half of 2027, the frontline Phase III TARGET-D 301 PDAC trial is expected to initiate before the end of 2026, and the frontline Phase III TARGET-D trials in CRC and non-small cell lung cancer are planned for the first half of 2027. The company expects an update across the program at the first of the year, multiple updates across the program in the next couple of months, the blister pack to launch in the first half of next year, 7375 plus gem/nab data in Q1 or Early Q2, and typically these Phase IIIs are 100 sites.
Verastem Risk Analysis
Verastem disclosed 67 risk factors in its most recent earnings report. Verastem reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksVerastem Peers Comparison
Overall Rating
PBYI64Neutral
ARVN49Neutral
CTMX47Neutral
ALLO46Neutral
BBOT39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PBYI | 64Neutral | $420.82M | 16.97 | 17.52% | ― | 9.35% | -37.15% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ARVN | 49Neutral | $453.16M | -46.07 | -2.00% | ― | -11.85% | 81.44% |
| CTMX | 47Neutral | $431.65M | -4.72 | -33.97% | ― | -87.66% | -210.45% |
| ALLO | 46Neutral | $322.87M | -1.43 | -49.84% | ― | ― | 36.37% |
| BBOT | 39Underperform | $176.38M | -0.00 | -49.01% | ― | ― | -132725.78% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0LOV | Verastem Inc | 8.91 | 0.58 | 6.94% | |
| PBYI | Puma Biotechnology | 8.08 | 3.13 | 63.23% | |
| CTMX | CytomX Therapeutics Inc. | 2.13 | -1.73 | -44.82% | |
| ARVN | Arvinas Holding Company | 6.91 | -3.21 | -31.72% | |
| ALLO | Allogene Therapeutics | 0.90 | -0.30 | -25.00% | |
| BBOT | Bridgebio Oncology Therapeutics, Inc. | 2.56 | -9.82 | -79.32% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.